Overview

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2032-06-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Phase:

PHASE1

Details

Lead Sponsor:

ModernaTX, Inc.